Submitted by Anonymous (not verified) on 21 November 2023 - 15:50
Human medicines European public assessment report (EPAR): Gavreto, pralsetinib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 18/11/2021, Revision: 6, Status: Authorised
Source: